Please login to the form below

Not currently logged in
Email:
Password:

InterMune

This page shows the latest InterMune news and features for those working in and with pharma, biotech and healthcare.

EU, US biotechs merge to create fibrosis, cancer player

EU, US biotechs merge to create fibrosis, cancer player

IPF is a debilitating and life-threatening condition that, until the approval of Roche/Intermune's Esbriet (pirfenidone) in 2011, had no approved drug treatments.

Latest news

More from news
Approximately 4 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    InterMune/ Roche. Company acquisition. Pirfenidone for idiopathic pulmonary fibrosis (IPF) (approved EU, Canada).

  • Pharma deals during August 2014 Pharma deals during August 2014

    Instead came the news that Roche had beaten a host of companies including Sanofi, GSK, Actelion and Gilead in the acquisition of InterMune for $8.3bn ($74.00 a share, representing ... InterMune is also developing a pirfenidone analogue to treat specialty

  • Orphan indication? No easy access Orphan indication? No easy access

    Only the case of Intermune's idiopathic pulmonary fibrosis drug Esbriet (perfenidone) was the balance of benefit and risk to patients considered and a finding of 'no proven added benefit' was

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Catabasis hires Rick Modi as its chief business officer Catabasis hires Rick Modi as its chief business officer

    Prior to joining Catabasis, Modi was senior vice president, global marketing at InterMune - an orphan drug company that was acquired by Roche late last year. ... He played a large role in the launch of InterMune's flagship product, the lung-scarring drug

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics